2348.HK HKSE
Dawnrays Pharmaceutical (Holdings) Limited
1W: +0.0%
1M: -2.5%
3M: -3.0%
YTD: -18.5%
1Y: -27.1%
3Y: -9.3%
5Y: -29.2%
HK$0.96 ($0.12)
-0.01 (-0.52%)
Weekly Expected Move ±2.0%
HK$1
HK$1
HK$1
HK$1
HK$1
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$220M
-34.9% ▼
5Y CAGR: -4.4%
Capital Expenditures
$176M
+17.2% ▲
5Y CAGR: +39.0%
Free Cash Flow
$45M
-64.7% ▼
5Y CAGR: -28.7%
Dividends Paid
$111M
+5.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$249M
+654.8% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $268M | $358M | $358M | $414M | $637M |
| Depreciation & Amort. | $56M | $56M | $64M | $84M | $0 |
| Stock-Based Comp. | $8M | $4M | -$5M | -$1M | -$511K |
| Change in Working Capital | -$25M | $12M | -$122M | $22M | -$229M |
| Other Non-Cash Items | -$21M | -$21M | $12M | -$181M | -$187M |
| Operating Cash Flow | $303M | $393M | $434M | $338M | $220M |
| — Investing Activities — | |||||
| Capital Expenditures | -$139M | -$313M | -$204M | -$200M | -$126M |
| Acquisitions (Net) | -$40M | $39M | $12M | $0 | $267M |
| Investment Purchases | -$1.5B | -$586M | -$746M | -$844M | -$480M |
| Investment Sales | $1.6B | $686M | $720M | $711M | $437M |
| Other Investing | $12M | -$110M | $43M | -$55M | $107M |
| Investing Cash Flow | $26M | -$284M | -$175M | -$388M | $205M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$217M | -$1M | $6M | $120M | -$75M |
| Stock Repurchased | -$40M | -$16M | $0 | $0 | $0 |
| Dividends Paid | -$82M | -$144M | -$100M | -$117M | -$111M |
| Other Financing | $11M | $29M | $61K | -$2M | -$4M |
| Financing Cash Flow | -$328M | -$130M | -$93M | $2M | -$189M |
| Net Change in Cash | -$135K | -$21M | $174M | -$45M | $249M |
| Cash End of Period | $258M | $238M | $412M | $367M | $616M |
| Free Cash Flow | $164M | $80M | $230M | $126M | $45M |